The opinion of the court was delivered by: Milton I. Shadur Senior United States District Judge
MEMORANDUM OPINION AND ORDER
In this patent infringement action between patentee Biopolymerengineering, Inc. d/b/a Biothera ("Biothera") and Massachusetts Institute of Technology as plaintiffs and claimed infringer Biorigin*fn1 ("Biorigin") as defendant, this Court set a schedule for cross-presentations by the litigants to facilitate an anticipated Markman determination construing any disputed claim terms. Both sides' counsel complied with that schedule and then appeared at a February 11 status hearing, also preset by this Court.*fn2 It developed at that hearing that a potentially dispositive determination might be made without delving into the arcane mysteries of â glucan that occupied the bulk of the cross-submissions.
By way of brief explanation, it turns out that all but one of the patents in dispute have concededly expired--only U.S. Patent No. 6,143,731 (the "'731 Patent") remains in issue. And because the parties confirmed during the status hearing that no material (if any) damages are potentially involved in the case, a determination by this Court that the '731 Patent has also expired is likely to permit a prompt resolution of the case itself.
Patent expiration dates are prescribed by 35 U.S.C. §154(a)(2)("Section 154(a)(2)"):*fn3
Subject to the payment of fees under this title, such grant shall be for a term beginning on the date on which the patent issues and ending 20 years from the date on which the application for the patent was filed in the United States or, if the application contains a specific reference to an earlier filed application or applications under section 120, 121, or 365(c) of this title, from the date on which the earliest such application was filed.
In this instance the critical dispute focuses not on the July 27, 1999 date of the application that ultimately matured in the '731 Patent, but rather on the October 28, 1988 date of Application Serial No. 07/264,091, which ultimately ripened into U.S. Patent 4,962,094. And in that respect it is undisputed that the application that led to the issuance of Patent '731 expressly claimed the benefit of that earlier October 1988 application (see Biorigin Mem. Exs. 26 and 27, signed by all three inventors).
Biothera R. Mem. at 6-7 seeks to escape the toils created by that unequivocal claim in the earlier application by invoking the provisions of the Manual of Patent Examining Procedure ("Manual" or "MPEP"), which sets out procedures for the Patent and Trademark Office's recognition of parties' efforts to obtain the benefit of earlier filing dates. But the Federal Circuit's view (as the Manual itself acknowledges) is that procedures set out in the Manual are not controlling--instead (as always) courts must look to the language of the statute itself.
Thus over two decades ago (coincidentally in the same year as the application that proves critical in this case) Ethicon, Inc. v. Quigg, 849 F.2d 1422, 1425 (Fed.Cir. 1988) (emphasis added) reflected that view:
The MPEP states that it is a reference work on patent practices and procedures and does not have the force of law, but it "has been held to describe procedures on which the public can rely."
And something over a decade later Atmel Corp. v. Info. Storage Devices, Inc., 198 F.3d 1374 (Fed. Cir. 1999) looked to the relevant statutory provision in reversing a District Court's grant of summary judgment that had looked to the Manual. As succinctly described in the dissenting opinion in Atmel (id. at 1384)*fn4
I agree that the MPEP does not control here. Although "the Commissioner of Patents is vested with wide discretion to formulate rules and guidelines governing [the] use [of incorporation by reference], thereby to prevent its abuse," In re Hawkins, 486 F.2d 569, 573, 179 USPQ 157, 161 (CCPA 1973), these guidelines do "not have the force of law," Ethicon, Inc. v. Quigg, 849 F.2d 1422, 1425, 7 USPQ2d 1152, 1154 (Fed. Cir.1988). "[T]he courts are the final authorities on issues of statutory construction. They must reject administrative constructions of [a] statute...that are inconsistent with the statutory mandate or that frustrate the policy that Congress sought to implement." Id. (quoting Federal Election Comm'n v. Democratic Senatorial Campaign Comm., 454 U.S. 27, 32, 102 S.Ct. 38, 70 L.Ed.2d 23 (1981)).
Nor are those statements of that basic principle the sole authorities that call for the rejection of Biothera's position. Even more directly, in Abbott Labs. v. Novopharm Ltd., 104 F.3d 1305 (Fed. Cir. 1997) the Federal Circuit affirmed a decision in which this Court's colleague Honorable Charles Kocoras had held (38 U.S.P.Q. 2d 1309 (N.D. Ill. 1996)): Furthermore, we do not believe that Section 154(a)(2) requires a patent holder to have actually benefited from the continuing or divisional application. Section 154(a)(2) simply states that we should consider the term length from the earliest filing date "if the application contains a specific reference to an earlier filed application or applications under sections 120, 121, or 365(c)." Because it is clear that the later application specifically referenced the earlier, we believe that we should consider the '097 patent term as beginning on October 14, 1975, the date on which the original application was filed, and expiring on October 14, 1995, twenty years later (the longer option provided under Section 154(c)(1)).
In rejecting essentially the same argument that is sought to be advanced by Biothera in this case, Abbott Labs., 104 F.3d at 1308 (footnote omitted) then had this to say after quoting Section 154(a)(2) and looking at the patent application there:
Abbott's argument that it should not be bound by the earlier filing date because it received no benefit from the divisional application is not persuasive. The district court found that Abbott chose to designate its patent as divisional in order to receive the potential benefits associated with the earlier filing date. Abbott's choice to do so cannot be disregarded simply because it subsequently found that the later filing date would be more advantageous. Abbott must accept the consequences as well as the potential benefits of the divisional status of the '895 application. During the February 11, 2009 status hearing, Biorigin's counsel submitted a previously-prepared "Citation of Additional Authority on Expiration of U.S. Patent 6,143,731," citing not only the District Court and Federal Circuit's opinions in Abbott Labs. but also Broadcast Innovation, L.L.C. v. Charter Commc'ns, Inc., 420 F.3rd 1364, 1366 (Fed.Cir. ...